| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NATTOPHARMA Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 62,80 | +2,38 % | Ionis Q1 2026 slides: commercial revenue surges, guidance raised | ||
| CSPC PHARMA | 0,892 | -1,37 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORISATION APPLICATION FOR AMPHOTERICIN B LIPOSOMAL, POWDER FOR CONCENTRATE FOR DISPERSION ... | ||
| SELLAS LIFE SCIENCES | 4,080 | -1,92 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,375 | 0,00 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 24,100 | -4,37 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026 | ||
| MADRIGAL PHARMACEUTICALS | 442,80 | +0,36 % | MADRIGAL PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OPUS GENETICS | 4,160 | -2,80 % | Citizens initiates Opus Genetics stock coverage with outperform rating | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets | Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,128 | -5,39 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,000 | 0,00 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 3,300 | 0,00 % | XFRA 5MP2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIODEXA PHARMA ADR... ► Artikel lesen | |
| CGN MINING | 0,440 | +2,80 % | CGN MINING (01164): LETTER TO NON-REGISTERED SHAREHOLDERS - NOTIFICATION FOR PUBLICATION OF ANNUAL REPORT 2025 | ||
| PHOTOCURE | 6,080 | -3,49 % | PHOTOCURE: Photocure ASA: Annual Report 2025 | ||
| ARCTICZYMES TECHNOLOGIES | 1,860 | -2,36 % | ARCTICZYMES TECHNOLOGIES: ArcticZymes Expands acib Collaboration and Joins CAARE Consortium to Advance Viral Vector Bioprocessing | ||
| NEURIZON THERAPEUTICS | 0,042 | -3,45 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 24.12.2025 | Das Instrument IBI JP3148800000 IBIDEN CO.LTD EQUITY wird cum Kapitalmassnahme gehandelt am 24.12.2025 und ex Kapitalmassnahme am 29.12.2025 The instrument IBI JP3148800000 IBIDEN CO.LTD EQUITY is traded... ► Artikel lesen |